Vibramycin®
doxycycline · oral capsule
Antibiotic
Approved uses
Trachoma caused by Chlamydia trachomatis
Adults, 200 mg on day 1 given as 100 mg every 12 hours, then 100 mg daily
Inclusion conjunctivitis caused by Chlamydia trachomatis
Adults, 200 mg on day 1 given as 100 mg every 12 hours, then 100 mg daily
OFF-LABELNot in the FDA label for this product
Meibomian gland dysfunction
20 mg twice daily for 1 month
Cochrane · very low certainty
A randomized trial in 150 patients with chronic meibomian gland dysfunction refractory to lid hygiene compared 20 mg twice daily, 200 mg twice daily and placebo: both active arms beat placebo on tear break-up time, Schirmer score and symptom counts at 1 month with no significant difference between the two doses, while side effects were more frequent on the high dose (39.13% versus 17.39%, P=0.002). A 2021 Cochrane review of oral antibiotics for chronic blepharitis pooled this and one other trial (220 participants total) and graded the evidence very low certainty for both symptoms and clinical signs.
Ocular rosacea
100 mg daily for 16 weeks
RCT · n=39 · no placebo arm
A randomized trial of 39 patients with moderate to severe papulopustular rosacea compared this regimen against low-dose oral isotretinoin: ocular symptoms and meibomian gland dysfunction grading improved more in the doxycycline arm (P<0.05), while the other measured parameters, best corrected acuity, Schirmer, break-up time and rose bengal staining, did not reach statistical significance.
Recurrent corneal erosion syndrome
50 mg twice daily with topical fluorometholone 0.1% three times daily for at least 4 weeks
Retrospective series · n=21
A retrospective single-observer case series of 21 patients reported 15 of 21 (71%) symptom free at 8 weeks, with 15 of 18 (83%) and 11 of 15 (73%) denying relapse at 6 and 12 months. An earlier retrospective interventional series of 7 eyes used 50 mg twice daily for 2 months plus a topical corticosteroid and saw pain resolve and epithelial defects heal within 2 to 10 days, with no recurrence over a mean 21.9 months. No randomized trial exists for this indication.
Contraindications
Hypersensitivity to any of the tetracyclines
50 mg capsules in bottles of 50; 100 mg capsules in bottles of 50 and 500
Inhibits bacterial protein synthesis by binding the 30S ribosomal subunit and has bacteriostatic activity against a broad range of Gram-positive and Gram-negative bacteria; it has been shown to be active against most isolates of Chlamydia trachomatis. Ocular surface use rests instead on a non-antibacterial effect, a reduction in matrix metalloproteinase-9 amount and activity in human corneal epithelial cultures.
Warnings & Precautions
- Intracranial hypertension: Associated with tetracyclines, presenting with headache, blurred vision, diplopia, vision loss and papilledema. Risk is greater in women of childbearing age who are overweight or have a history of intracranial hypertension. It typically resolves after discontinuation, but permanent visual loss is possible. Visual disturbance during treatment warrants prompt ophthalmologic evaluation, and since pressure can stay elevated for weeks after stopping, monitor patients until they stabilize.
- Pseudotumor cerebri: Concomitant use of isotretinoin should be avoided because isotretinoin is also known to cause pseudotumor cerebri.
- Tooth discoloration: Tetracycline-class drugs used during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent yellow-gray-brown discoloration of the teeth, more common with long-term use but also observed after repeated short-term courses; enamel hypoplasia has also been reported. At 8 years of age or less, use only when benefits are expected to outweigh risks in severe or life-threatening conditions, particularly when there are no alternative therapies.
- Clostridioides difficile associated diarrhea: Reported with nearly all antibacterial agents and may range from mild diarrhea to fatal colitis. Consider it in all patients with diarrhea after antibacterials; take a careful history, since it has been reported over two months later. If suspected or confirmed, antibacterials not directed against C. difficile may need to be stopped, with fluid and electrolyte management, protein supplementation, C. difficile treatment and surgical evaluation as clinically indicated.
- Severe skin reactions: Exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS; fixed drug eruptions can worsen on re-exposure, including generalized bullous forms. Discontinue immediately and treat.
- Photosensitivity: Exaggerated sunburn reaction in some patients on tetracyclines; stop treatment at the first sign of skin erythema.
- Skeletal effects: Tetracyclines form a stable calcium complex in any bone-forming tissue, and a decrease in fibula growth rate occurred in premature infants given oral tetracycline in doses of 25 mg/kg every 6 hours; this was reversible when the drug was discontinued.
- Hazard to the fetus: Animal studies indicate tetracyclines cross the placenta, are found in fetal tissues and can have toxic effects on the developing fetus (often related to retardation of skeletal development), and embryotoxicity has been noted in animals treated early in pregnancy. If any tetracycline is used during pregnancy or the patient becomes pregnant while taking it, apprise the patient of the potential hazard to the fetus.
- BUN elevation: The antianabolic action of tetracyclines can raise BUN, though studies to date indicate this does not occur with doxycycline in patients with impaired renal function.
- Impaired absorption: Antacids containing aluminum, calcium or magnesium, iron-containing preparations and bismuth subsalicylate all impair tetracycline absorption.
- Lowered doxycycline concentration: Barbiturates, carbamazepine, phenytoin and rifampin shorten the half-life and lower drug concentrations.
- Depressed plasma prothrombin activity: Tetracyclines have been shown to depress plasma prothrombin activity, so patients on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
- Interference with bactericidal action: Bacteriostatic drugs may interfere with the bactericidal action of penicillin, so concurrent use is not advised.
- Reduced contraceptive effectiveness: Concurrent tetracycline may render oral contraceptives less effective.
- Superinfection: Use may result in overgrowth of nonsusceptible organisms, including fungi; if superinfection occurs, discontinue and institute appropriate therapy. Doxycycline might increase the incidence of vaginal candidiasis.
- Drug-resistant bacteria: Prescribing in the absence of proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit and increases the risk of drug-resistant bacteria.
- Surgical procedures: Incision and drainage or other surgical procedures should be performed in conjunction with antibacterial therapy, when indicated.
- Incomplete malaria suppression: Doxycycline offers substantial but not complete suppression of the asexual blood stages of Plasmodium strains and does not suppress P. falciparum's sexual blood stage gametocytes, so subjects may still transmit the infection to mosquitoes outside endemic areas; no present-day antimalarial agent guarantees protection.
- Laboratory tests: When co-existent syphilis is suspected in venereal disease, do dark field examinations before treatment and repeat blood serology monthly for at least 4 months; in long-term therapy, perform periodic hematopoietic, renal and hepatic studies.
- False elevations of urinary catecholamine levels: May occur due to interference with the fluorescence test.
Common Side Effects
Gastrointestinal reactions include anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis and pancreatitis; hepatotoxicity has been reported rarely, and rare esophagitis and esophageal ulcerations have been reported, mostly in patients who took the drug immediately before going to bed. Skin reactions include toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, fixed drug eruption, skin hyperpigmentation and rashes. Permanent tooth discoloration and enamel hypoplasia may occur during tooth development. Hypersensitivity reactions include urticaria, angioneurotic edema, anaphylaxis, serum sickness, pericarditis and DRESS. Hemolytic anemia, thrombocytopenia, neutropenia, eosinophilia, depression, anxiety, suicidal ideation, a rise in BUN that is apparently dose related, and intracranial hypertension in adults have been reported.
Pregnancy: No adequate and well-controlled studies in pregnant women; most reported experience is short-term, first trimester exposure, and no human data assess long-term therapy. A TERIS expert review concluded therapeutic doses are unlikely to pose a substantial teratogenic risk, on data graded limited to fair, but insufficient to state there is no risk; a case-control study showed a weak, marginally significant association with total malformations that was not seen when analysis was confined to organogenesis, except for a marginal relationship with neural tube defect based on only two exposed cases. A small prospective study of 43 women treated for 10 days in early first trimester reported all exposed infants normal at 1 year of age. Animal studies indicate tetracyclines cross the placenta, and use in the last half of pregnancy may cause permanent tooth discoloration.
Lactation: Excreted in human milk, with the extent of infant absorption unknown. Short-term use by a lactating woman is not necessarily contraindicated, but the effects of prolonged exposure through milk are unknown. Because of the potential for serious adverse reactions in nursing infants, decide whether to discontinue nursing or the drug, taking into account the importance of the drug to the mother.
In pediatric patients 8 years of age or less, use only when the potential benefits are expected to outweigh the risks in severe or life-threatening conditions (e.g., anthrax, Rocky Mountain spotted fever), particularly when there are no alternative therapies, because of effects on tooth development and growth.